Skip to main content
PRESCIENT THERAPEUTICS LIMITED logo

PRESCIENT THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PTX ISIN · AU000000PTX3 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,006 across all filing types
Latest filing 2024-12-10 Director's Dealing
Country AU Australia
Listing ASX PTX

About PRESCIENT THERAPEUTICS LIMITED

https://ptxtherapeutics.com/

Prescient Therapeutics Limited is a clinical-stage oncology company focused on developing personalized medicine and innovative cancer treatments. The company leverages two primary technology pillars: modular cell therapies and targeted small molecule inhibitors. Its flagship OmniCAR platform is a universal, multi-arm CAR-T system designed to provide clinicians with enhanced control and flexibility over cell therapy treatments, addressing limitations such as antigen escape and toxicity. Complementing this is the CellPryme platform, which optimizes cell therapy performance through improved manufacturing and efficacy. Additionally, Prescient maintains a pipeline of targeted therapies, including PTX-100, a first-in-class prenylation inhibitor targeting the Ras pathway, and PTX-200, an AKT inhibitor. These programs aim to treat various hematological malignancies and solid tumors by addressing specific genetic drivers of cancer.

Recent filings

Filing Released Lang Actions
Change of Director's Interest Notice 3 pages 226.7KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings and interests of a company director, including shares and options acquired. The content focuses exclusively on the director's personal share transactions and interests, with no financial performance data or other report content. This matches the definition of Director's Dealing filings, which report personal share transactions by company directors and executives (insider trades). The document length and content confirm it is not an announcement or a report but the actual notice of director's interest change.
2024-12-10 English
Notification of cessation of securities - PTX 4 pages 14.8KB
Share Issue/Capital Change Classification · 95% confidence The document is an announcement from Prescient Therapeutics Limited regarding the cessation of certain securities, specifically the expiry of options that were unexercised. It details the number of securities that have ceased, the reason for cessation (expiry of options), and the updated issued capital following these changes. There are no financial statements, management discussion, or detailed financial data present. The document is a regulatory announcement about changes in the company's capital structure due to option expiry, not a full financial report or earnings release. This fits the category of Share Issue/Capital Change (SHA), as it relates to changes in issued securities and capital structure.
2024-12-03 English
Change of Director's Interest Notices x4 12 pages 1.4MB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y – Change of Director's Interest Notices' and discusses the late lodgement of these notices for four directors. It details changes in directors' relevant interests in securities, including shares and options, and references compliance with ASX Listing Rules 3.19A and 3.19B. The content focuses on reporting personal share transactions and interests of company directors. There is no financial performance data, earnings information, or management discussion. The document is a formal notification of insider share transactions by directors, which aligns with the definition of Director's Dealing filings.
2024-12-03 English
Chair and CEO AGM Presentation 33 pages 2.1MB
AGM Information Classification · 100% confidence The document is titled '2024 AGM presentation' and contains detailed presentation slides including a Chair Address, company accomplishments, clinical trial updates, strategy, and sector challenges. It includes forward-looking statements and disclaimers typical of investor presentations. The content is consistent with materials shared during an Annual General Meeting (AGM) to inform shareholders about company progress and plans. There is no indication that this is a full annual report, earnings release, or regulatory filing. The length (15,000 characters) and detailed slide content confirm it is a presentation rather than a brief announcement or certification. Therefore, the document fits the category of AGM Information (AGM-R).
2024-11-13 English
Results of Annual General Meeting 2 pages 692.1KB
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is dated 14 November 2024 and is addressed to the ASX Limited Market Announcements Office. It explicitly states it is the "RESULTS OF 2024 ANNUAL GENERAL MEETING" and provides detailed voting results for each resolution proposed at the AGM, including adoption of remuneration report, election and re-election of directors, approval of options issuance, renewal of takeover provisions, placement facility approval, and spill resolution. The document references compliance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, which govern disclosure of voting results. The content is focused solely on the official announcement of the voting outcomes from the AGM, not the AGM materials or the meeting itself. The document length is 3374 characters, which is relatively short and consistent with a voting results announcement rather than a full AGM report or presentation. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2024-11-13 English
September 2024 Quarterly Update and Appendix 4C 10 pages 487.5KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'September 2024 Activities Report and Appendix 4C' and includes a quarterly cash flow statement (Appendix 4C) along with an activities report for the September 2024 quarter. It contains detailed financial data such as cash reserves, net operating expenditure, and R&D investment, as well as operational updates on clinical trials and company activities. The presence of substantive financial data and analysis for a quarter, combined with operational commentary, indicates this is a comprehensive interim/quarterly report rather than a brief announcement or regulatory filing. The document length (15,000 characters) and content depth support classification as an Interim / Quarterly Report (IR). Q1 2025
2024-10-30 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.